Here’s a startling fact: Breast cancer, excluding skin cancers, is the most frequently diagnosed cancer among women in the United States, accounting for nearly 30% of all new female cancer cases annually. By 2026, the American Cancer Society predicts a staggering 322,000 new cases of invasive breast cancer and 61,000 cases of ductal carcinoma in situ among U.S. women, with approximately 42,140 lives lost to the disease. But here’s where it gets even more critical: a groundbreaking study has uncovered a potential game-changer in predicting recurrence for HER2-positive breast cancer patients.
Researchers have discovered that the presence of circulating tumor DNA (ctDNA) after neoadjuvant treatment with T-DM1 could be a powerful predictor of cancer recurrence. This finding is particularly eye-opening because it holds true even for patients who achieve a pathologic complete response (pCR), a condition typically associated with better outcomes. The study, published in Cancer Research Communications by Lin et al., highlights ctDNA as an independent prognostic factor that could revolutionize how we approach adjuvant therapy for HER2-positive early breast cancer.
But here’s where it gets controversial: While pCR has long been considered the gold standard for assessing treatment success, this research suggests that ctDNA might be an even more reliable indicator of long-term outcomes. Could this mean we’ve been missing a critical piece of the puzzle in cancer care? And if so, what does this imply for current treatment protocols?
Study Methodology
The researchers conducted a retrospective analysis of 117 patients with HER2-positive early-stage breast cancer who received neoadjuvant systemic therapy. This included chemotherapy combined with single or dual anti-HER2 antibodies, such as trastuzumab or pertuzumab, alongside taxane chemotherapy. Notably, 18 patients also received the antibody-drug conjugate T-DM1 post-surgery, a treatment known to improve survival in patients without pCR, as demonstrated in the KATHERINE trial. Blood samples were collected before neoadjuvant therapy began to assess ctDNA levels.
Key Findings
Of the 117 patients, 25 achieved pCR, yet 6 of these still tested positive for ctDNA. Among the 92 non-pCR patients, ctDNA positivity after neoadjuvant therapy was a strong independent predictor of cancer recurrence, with a hazard ratio of 5.505 (P = .001). Even more striking, pCR patients with ctDNA positivity experienced significantly shorter recurrence-free survival compared to those without ctDNA (P = .008). Conversely, non-pCR patients with ctDNA-negative tumors had better outcomes (P = .001).
For patients who were ctDNA-positive before treatment, clearing ctDNA through neoadjuvant therapy was linked to markedly improved recurrence-free survival (P < .001). Additionally, adjuvant T-DM1 therapy significantly boosted ctDNA clearance rates (P = .035) in patients who remained ctDNA-positive after initial treatment. When patients were grouped by T-DM1 use and ctDNA status, those who were ctDNA-positive and did not receive T-DM1 had the shortest recurrence-free survival (P = .029).
And this is the part most people miss: Lead author Chiun-Sheng Huang, MD, PhD, MPH, suggests that ctDNA could outperform pCR as a prognostic tool for HER2-positive early breast cancer patients post-neoadjuvant therapy. This raises a critical question: Should we reconsider how we tailor adjuvant therapies based on ctDNA status rather than relying solely on pCR?
Significance and Future Directions
While these findings are promising, Huang emphasizes the need for larger, randomized trials to validate these implications. If confirmed, ctDNA could become a cornerstone in personalizing treatment, guiding decisions to escalate or de-escalate adjuvant therapy. However, this shift could spark debate among oncologists and researchers, as it challenges established practices.
What do you think? Is ctDNA the future of breast cancer prognostics, or is it too early to abandon traditional markers like pCR? Share your thoughts in the comments below.
Disclosure: This study was funded by the Taiwan National Science and Technology Council, the National Taiwan University Hospital, and the Yonglin Foundation. Full author disclosures are available at the study’s publication link. The content in this post has not been reviewed by the American Society of Clinical Oncology (ASCO®) and does not necessarily reflect ASCO®’s views.
